Related Experiment Video
Updated: Aug 11, 2026

Determination of the Relative Potency of an Anti-TNF Monoclonal Antibody (mAb) by Neutralizing TNF Using an In Vitro Bioanalytical Method
Published on: September 16, 2017
An APRIL to remember: novel TNF ligands as therapeutic targets
Stacey R Dillon1, Jane A Gross, Stephen M Ansell
1Department of Autoimmunity and Inflammation, ZymoGenetics, Inc. 1201 Eastlake Avenue East, Seattle, Washington 98102, USA. dillons@zgi.com
Abstract:
Since their discovery in 1998, the two TNF family members APRIL and BLyS/BAFF have received increasing attention. In addition to regulating normal B-cell development and immune responses, these molecules might be crucial in a diverse set of diseases, including autoimmunity and cancer. Although more has been published about the general biology of BLyS/BAFF than that of APRIL, many recent articles have described novel APRIL biology. Here we focus on APRIL, exploring its normal and pathological functions, and comparing the therapeutic molecules currently under development that target BLyS/BAFF alone, or APRIL and BLyS/BAFF together.
Related Concept Videos
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include: